Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of rituximab (MabThera) for paediatric patients

CHMP recommended license extensions for severe granulomatosis with polyangiitis and microscopic polyangiitis; and for diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt leukaemia or Burkitt-like lymphoma.

European Medicines Agency